These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9559310)

  • 1. Tumor resistance to antimetabolites.
    Kinsella AR; Smith D
    Gen Pharmacol; 1998 May; 30(5):623-6. PubMed ID: 9559310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):1-82. PubMed ID: 7481838
    [No Abstract]   [Full Text] [Related]  

  • 3. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
    Hung SW; Mody HR; Govindarajan R
    Cancer Lett; 2012 Jul; 320(2):138-49. PubMed ID: 22425961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
    Vakhabova JV; Semenov NN; Dobrova NV; Lichinitser MR
    Bull Exp Biol Med; 2008 Feb; 145(2):249-51. PubMed ID: 19023981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
    Kinsella AR; Smith D; Pickard M
    Br J Cancer; 1997; 75(7):935-45. PubMed ID: 9083327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anticancer agents in clinical development.
    Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
    Oncology (Williston Park); 1995 Dec; 9(12):1321-8; 1331; discussion 1332-4. PubMed ID: 8771106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of new chemotherapeutic agents.
    Hanauske AR
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():29-32. PubMed ID: 8862708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colon cancer: new drug options improve on 5-FU.
    McCann J
    J Natl Cancer Inst; 1998 Jul; 90(13):963-5. PubMed ID: 9665142
    [No Abstract]   [Full Text] [Related]  

  • 10. Gemcitabine and UFT plus oral calcium folinate: phase I study.
    Philip PA; Ibrahim D; Zalupski M; Arlauskas P; Shields A
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):116-9. PubMed ID: 10442378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
    Nutting C; Folkes A
    Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
    [No Abstract]   [Full Text] [Related]  

  • 12. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
    Clarke ML; Mackey JR; Baldwin SA; Young JD; Cass CE
    Cancer Treat Res; 2002; 112():27-47. PubMed ID: 12481710
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges of drug resistance in the management of pancreatic cancer.
    Sheikh R; Walsh N; Clynes M; O'Connor R; McDermott R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1647-61. PubMed ID: 20942635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I inhibitors and other new cytotoxic drugs.
    Verweij J
    Eur J Cancer; 1995; 31A(5):828-30. PubMed ID: 7640070
    [No Abstract]   [Full Text] [Related]  

  • 18. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
    Mohelníková-Duchonová B; Soucek P
    Klin Onkol; 2010; 23(5):306-10. PubMed ID: 21061681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
    Ueno H; Kiyosawa K; Kaniwa N
    Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.